The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene

International Journal of Cancer

Volumn 125, Issue 12, 2009, Pages 2810-2819

  Daniel Carmi, Vered ^a   Makovitzki Avraham, Efrat ^a   Reuven, Eliran Moshe ^a   Goldstein, Ido ^a   Zilkha, Noga ^a   Rotter, Varda ^a   Tzehoval, Esther ^a   Eisenbach, Lea ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Apoptosis; Cell cycle; Colon cancer; IFITM2; Interferon; p53

Indexed keywords

CASPASE; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; ETOPOSIDE; LIPOCORTIN 5; PROTEIN P53;

1 8D GENE; ALLELE; ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING ASSAY; CELL CYCLE G1 PHASE; CELL DEATH; CELL GROWTH; COLON; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; ULTRAVIOLET RADIATION;

AMINO ACID SEQUENCE; ANIMALS; ANNEXIN A5; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CASPASES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EMBRYO, MAMMALIAN; FIBROBLASTS; G1 PHASE; HUMANS; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 72449121041     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24669     Document Type: Article

References (63)

1. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32. (Pubitemid 39576902)
2. Tirosh B, Daniel-Carmi V, Carmon L, Paz A, Lugassy G, Vadai E, Machlenkin A, Bar-Haim E, Do MS, Ahn IS, Fridkin M, Tzehoval E, et al. '1-8 interferon inducible gene family': putative colon carcinoma-associated antigens. Br J Cancer 2007;97:1655-1663
3. Lewin AR, Reid LE, McMahon M, Stark GR, Kerr IM. Molecular analysis of a human interferon-inducible gene family. Eur J Biochem 1991;199:417-423
4. Kelly JM, Gilbert CS, Stark GR, Kerr IM. Differential regulation of interferon-induced mRNAs and c-myc mRNA by alpha- and gamma-interferons. Eur J Biochem 1985;153:367-371
5. Andreu P, Colnot S, Godard C, Laurent-Puig P, Lamarque D, Kahn A, Perret C, Romagnolo B. Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res 2006;66:1949-1955 (Pubitemid 43294902)
6. Daido H, Zhou MY, Gomez-Sanchez CE. Angiotensin stimulates the expression of interferon-inducible genes in H295R cells. Mol Cell Endocrinol 2001;176:21-27 (Pubitemid 32454931)
7. Chan EC, Fraser S, Yin S, Yeo G, Kwek K, Fairclough RJ, Smith R. Human myometrial genes are differentially expressed in labor: a suppression subtractive hybridization study. J Clin Endocrinol Metab 2002;87:2435-2441 (Pubitemid 34655296)
8. Deblandre GA, Marinx OP, Evans SS, Majjaj S, Leo O, Caput D, Huez GA, Wathelet MG. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J Biol Chem 1995;270:23860-23866
9. Yang G, Xu Y, Chen X, Hu G. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene 2007;26:594-603. (Pubitemid 46160972)
10. Lange UC, Saitou M, Western PS, Barton SC, Surani MA. The fragilis interferon-inducible gene family of transmembrane proteins is associated with germ cell specification in mice. BMC Dev Biol 2003;3:1. (Pubitemid 38783252)
11. Lange UC, Adams DJ, Lee C, Barton S, Schneider R, Bradley A, Surani MA. Normal germ line establishment in mice carrying a deletion of the Ifitm/Fragilis gene family cluster. Mol Cell Biol 2008;28:4688-4696
12. Saitou M, Barton SC, Surani MA. A molecular programme for the specification of germ cell fate in mice. Nature 2002;418:293-300. (Pubitemid 34790674)
13. Tanaka SS, Nagamatsu G, Tokitake Y, Kasa M, Tam PP, Matsui Y. Regulation of expression of mouse interferon-induced transmembrane protein like gene-3. Ifitm3 (mil-1, fragilis), in germ cells. Dev Dyn 2004;230:651-659
14. Smith RA, Young J, Weis JJ, Weis JH. Expression of the mouse fragilis gene products in immune cells and association with receptor signaling complexes. Genes Immun 2006;7:113-121 (Pubitemid 43336053)
15. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-1501 (Pubitemid 28538613)
16. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55:5187-5190
17. Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, Kondratov R, Stark GR, Chumakov PM, Gudkov AV. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci USA 1996;93:10309-10314 (Pubitemid 26314618)
18. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-915 (Pubitemid 20268298)
19. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-723 (Pubitemid 28155311)
20. Finlay C. Rat embryo fibroblast complementation assay with ras genes. Methods Enzymol 1995;255:389-394
21. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596-602.
22. Chu YW, Wang R, Schmid I, Sakamoto KM. Analysis with flow cytometry of green fluorescent protein expression in leukemic cells. Cytometry 1999;36:333-339 (Pubitemid 29344469)
23. Chow KC, Ross WE. Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol 1987;7:3119-3123
24. Sordet O, Khan QA, Kohn KW, Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anticancer Agents 2003;3:271-290
25. Tran YK, Newsham IF. High-density marker analysis of 11p15.5 in non-small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. Cancer Res 1996;56:2916-2921
26. Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, Carter SL, Rosenberg AL, Schwartz GF, Shiloh Y, Cavenee WK, Croce CM. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res 1995;55:3003-3007
27. Catchpoole D, Lam WW, Valler D, Temple IK, Joyce JA, Reik W, Schofield PN, Maher ER. Epigenetic modification and uniparental inheritance of H19 in Beckwith-Wiedemann syndrome. J Med Genet 1997;34:353-359 (Pubitemid 27226671)
28. Lu KH, Weitzel JN, Kodali S, Welch WR, Berkowitz RS, Mok SC. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res 1997;57:387-390 (Pubitemid 27081651)
29. O'Briant KC, Bepler G. Delineation of the centromeric and telomeric chromosome segment 11p15.5 lung cancer suppressor regions LOH11A and LOH11B. Genes Chromosomes Cancer 1997;18:111-114 (Pubitemid 27068909)
30. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-1787 (Pubitemid 27136714)
31. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 1994;5:221-227 (Pubitemid 124006732)
32. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature 1996;381:643-644
33. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604. (Pubitemid 37328926)
34. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825
35. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-649
36. Kaluzova M, Kaluz S, Lerman MI, Stanbridge EJ. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol 2004;24:5757-5766 (Pubitemid 38787961)
37. Ratovitski EA, Patturajan M, Hibi K, Trink B, Yamaguchi K, Sidransky D. p53 associates with and targets Delta Np63 into a protein degradation pathway. Proc Natl Acad Sci USA 2001;98:1817-1822 (Pubitemid 32165581)
38. Pochampally R, Fodera B, Chen L, Lu W, Chen J. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J Biol Chem 1999;274:15271-15277 (Pubitemid 129518868)
39. Gottlieb E, Oren M. p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. Embo J 1998;17:3587-3596 (Pubitemid 28327377)
40. Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V. p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem 2004;279:50976-50985 (Pubitemid 40017838)
41. Taylor WR, Schonthal AH, Galante J, Stark GR. p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J Biol Chem 2001;276:1998-2006. (Pubitemid 32109679)
42. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759-5769 (Pubitemid 39093021)
43. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. Embo J 1993;12:461-468 (Pubitemid 23073692)
44. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299 (Pubitemid 27220766)
45. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999;274:5053-5060 (Pubitemid 129501525)
46. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-290 (Pubitemid 32250377)
47. Clave E, Carosella ED, Gluckman E, Socie G. Radiation-enhanced expression of interferon-inducible genes in the KG1a primitive hematopoietic cell line. Leukemia 1997;11:114-119 (Pubitemid 27065057)
48. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H, Janicke RU, Porter AG, Belka C, Gregor M, Schulze-Osthoff K, et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 2000;19:4563-4573 (Pubitemid 30777624)
49. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dorken B, Daniel PT. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001;97:1378-1387 (Pubitemid 32183762)
50. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000;60:7133-7141 (Pubitemid 32059195)
51. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, Debatin KM. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 1998;273:33942-33948 (Pubitemid 29008858)
52. Pirnia F, Schneider E, Betticher DC, Borner MM. Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. Cell Death Differ 2002;9:905-914 (Pubitemid 35023606)
53. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8:237-249 (Pubitemid 36749609)
54. Kim SH, Gunnery S, Choe JK, Mathews MB. Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase. PKR. Oncogene 2002;21:8741-8748 (Pubitemid 36132395)
55. Cooper HS, Murthy S, Kido K, Yoshitake H, Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology. B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000;21:757-768
56. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205. (Pubitemid 28307304)
57. Ingber DE. Integrins, tensegrity, and mechanotransduction. Gravit Space Biol Bull 1997;10:49-55.
58. Maniotis AJ, Chen CS, Ingber DE. Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure. Proc Natl Acad Sci USA 1997;94:849-854
59. Ingber D. Integrins as mechanochemical transducers. Curr Opin Cell Biol 1991;3:841-848
60. Ingber DE, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol 1989;109:317-330 (Pubitemid 19180139)
61. Bateman WJ, Donnellan I, Fraser IA, Wong LS, Morris AG. Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma. Cancer Immunol Immunother 1995;41:61-67
62. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005;307:1904-1909 (Pubitemid 40404692)
63. Tanaka SS, Yamaguchi YL, Tsoi B, Lickert H, Tam PP. IFITM/Mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Dev Cell 2005;9:745-56.